SCHEMBL2139015

SCHEMBL2139015

CC(C)(Cc1cccc(CO)c1)NC(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
ALDH1A1 P00352 2/20 0.49
PDK1 Q15118 1/20 0.43
PDK2 Q15119 1/20 0.43
PDK3 Q15120 1/20 0.43
PDK4 Q16654 1/20 0.43
CYP2D6 P10635 2/20 0.41
LMNA P02545 1/20 0.41
OPRM1 P35372 2/20 0.40
OPRD1 P41143 2/20 0.40
OPRK1 P41145 2/20 0.40
ADRB2 P07550 1/20 0.39
IKBKB O14920 1/20 0.39
ACMSD Q8TDX5 1/20 0.38
SHMT1 P34896 1/20 0.37
SHMT2 P34897 1/20 0.37
REN P00797 1/20 0.37
CYP1A2 P05177 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6111389 0.86 CYP2C9 (0.50) CYP3A4CYP2C9CYP2C19ALDH1A1CYP2D6
SCHEMBL2824494 0.84 CYP2C19 (0.49) CYP3A4CYP2C9CYP2C19ALDH1A1CYP2D6
SCHEMBL5948337 0.83 CYP3A4 (0.67) CYP3A4CYP2C9CYP2C19ALDH1A1CYP2D6
SCHEMBL5667467 0.83 ALDH1A1 (0.48) CYP3A4CYP2C9CYP2C19ALDH1A1NPC1
SCHEMBL2139709 0.82 ALDH1A1 (0.41) CYP3A4CYP2C9CYP2C19ALDH1A1PDK1
SCHEMBL18459510 0.80 ALDH1A1 (0.50) CYP3A4CYP2C9CYP2C19ALDH1A1CYP2D6
SCHEMBL6110413 0.79 LMNA (0.47) CYP3A4CYP2C9CYP2C19ALDH1A1PDK1
SCHEMBL6111376 0.79 RIPK1 (0.43) CYP3A4CYP2C9CYP2C19ALDH1A1CYP2D6
SCHEMBL10294037 0.79 ENPP2 (0.45) PDK1PDK2PDK3PDK4IKBKB
SCHEMBL28665575 0.76 CYP4F2 (0.42) CYP3A4CYP2C9CYP2C19ALDH1A1PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629271-B2 Compounds ASTRAZENECA AB (GB) 2014-01-14 US disclosed
US-20120322788-A1 Compouds PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2012-12-20 US disclosed
EP-2242759-B1 COMPOUNDS ASTRAZENECA AB (SE) 2012-09-12 EP disclosed
US-8148373-B2 Compounds ASTRAZENECA AB (SE) 2012-04-03 US disclosed
US-20090298807-A1 Compounds ASTRAZENECA AB (SE) 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120322788-A1 Compouds PKD1, SBDS, ABCB11 CYP3A4 76/4885CYP2C9 31/4885CYP2C19 19/4885
US-20090298807-A1 Compounds PKD1, SLC10A1, ABCB11 CYP3A4 60/4885CYP2C9 22/4885CYP2C19 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.